Puma Biotechnology | PBYI - Current Liabilities


Puma Biotechnology reported $82.73M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Exelixis USD 405.64M 31.86M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Moderna USD 1.99B 306M Dec/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025